This company listing is no longer active
Liminal BioSciences Past Earnings Performance
Past criteria checks 0/6
Liminal BioSciences has been growing earnings at an average annual rate of 30.6%, while the Biotechs industry saw earnings growing at 27% annually. Revenues have been declining at an average rate of 72.7% per year.
Key information
30.6%
Earnings growth rate
72.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -72.7% |
| Return on equity | -79.9% |
| Net Margin | -7,241.4% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Liminal BioSciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -29 | 18 | 0 |
| 30 Sep 22 | 0 | -31 | 20 | 0 |
| 30 Jun 22 | 1 | -35 | 25 | 0 |
| 31 Mar 22 | 0 | -42 | 29 | 0 |
| 31 Dec 21 | 1 | -44 | 32 | 0 |
| 30 Sep 21 | 1 | -48 | 34 | 0 |
| 30 Jun 21 | 1 | -49 | 32 | 0 |
| 31 Mar 21 | 1 | -35 | 30 | 0 |
| 31 Dec 20 | 1 | -48 | 33 | 0 |
| 30 Sep 20 | 1 | -75 | 35 | 0 |
| 30 Jun 20 | 2 | -94 | 38 | 0 |
| 31 Mar 20 | 3 | -232 | 49 | 0 |
| 31 Dec 19 | 1 | -150 | 38 | 0 |
| 30 Sep 19 | -8 | -299 | 44 | 0 |
| 30 Jun 19 | 3 | -298 | 40 | 0 |
| 31 Mar 19 | 23 | -194 | 29 | 0 |
| 31 Dec 18 | 25 | -197 | 29 | 0 |
| 30 Sep 18 | 43 | -131 | 50 | 0 |
| 30 Jun 18 | 55 | -118 | 52 | 0 |
| 31 Mar 18 | 39 | -115 | 53 | 0 |
| 31 Dec 17 | 22 | -112 | 50 | 0 |
| 30 Sep 17 | 37 | -109 | 32 | 0 |
| 30 Jun 17 | 16 | -119 | 31 | 0 |
| 31 Mar 17 | 16 | -112 | 28 | 0 |
| 31 Dec 16 | 16 | -101 | 26 | 0 |
| 30 Sep 16 | 26 | -74 | 22 | 0 |
| 30 Jun 16 | 28 | -58 | 19 | 0 |
Quality Earnings: PJ2 is currently unprofitable.
Growing Profit Margin: PJ2 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PJ2 is unprofitable, but has reduced losses over the past 5 years at a rate of 30.6% per year.
Accelerating Growth: Unable to compare PJ2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PJ2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.2%).
Return on Equity
High ROE: PJ2 has a negative Return on Equity (-79.86%), as it is currently unprofitable.